F18‑fluorodeoxyglucose positron emission tomography/computed tomography for bone hemangiopericytoma

  • Liu Y
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Bone hemangiopericytoma (HPC) is extremely rare, and its clinical manifestations and radiographic features are nonspecific. There are few case reports about application of F18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in HPC. A total of four subjects with pathologically diagnosed bone HPC had FDG PET/CT for staging and/or restaging bone HPC. Medical records were retrospectively reviewed for radiological, pathological and follow-up information. All primary bone and metastatic lesions demonstrated high FDG avidity on PET/CT, which also revealed the adjacent soft tissue involvement and synchronous lesion. PET/CT correctly detected metastatic lesions in 1 patient. Furthermore, 3/4 patients with available laboratory data had hypocalcemia, but normal phosphorus levels when HPC existed as primary lesions or metastatic disease; however, normalization of calcium levels when they were disease-free. The results suggested that FDG PET/CT could be effectively used for staging, surveillance and detection of recurrent/metastatic disease in HPC. There may be an association between bone HPC and hypocalcemia.

Cite

CITATION STYLE

APA

Liu, Y. (2017). F18‑fluorodeoxyglucose positron emission tomography/computed tomography for bone hemangiopericytoma. Molecular and Clinical Oncology. https://doi.org/10.3892/mco.2017.1458

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free